Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Sarepta Therapeutics's Patidistrogene bexoparvovec?
Patidistrogene bexoparvovec is a gene therapy commercialized by Sarepta Therapeutics, with a leading Phase II program in Limb-Girdle Muscular Dystrophy....
Data Insights
Risk adjusted net present value: What is the current valuation of Sarepta Therapeutics's Patidistrogene bexoparvovec?
Patidistrogene bexoparvovec is a gene therapy commercialized by Sarepta Therapeutics, with a leading Phase II program in Limb-Girdle Muscular Dystrophy....